US · PDSB · BIOTECHNOLOGY
PDS Biotechnology Corporation (PDSB) intrinsic value and stock valuation
$0.78as of 2026-11-21 · Mkt cap 40.64M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
PDS Biotechnology Corporation DCF and intrinsic value
InvestorsCraft values PDSB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PDSB’s statements →
PDS Biotechnology Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-31.54M | -$-36.32M | -$-43.05M | -$-41.67M | -$-21.44M |
| Net income | -$-34.5M | -$-37.61M | -$-42.94M | -$-40.85M | -$-16.92M |
| EPSd | -$-743.86K | -$-1.03M | -$-1.39M | -$-1.43M | -$-660.94K |
| Operating cash flow | -$-27.75B | -$-35.03M | -$-33.64M | -$-25.71M | -$-12.49M |
| Capital expenditure | $0.00 | -$-30K | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-27.75B | -$-35.06M | -$-33.64M | -$-25.71M | -$-12.49M |
| Total assets | $30.5M | $45.4M | $59.4M | $77M | $67.2M |
| Total debt | $16.9M | $21.8M | $23.9M | $23.5M | $490K |
| Net debt | -$-9.79M | -$-19.86M | -$-32.71M | -$-50.35M | -$-64.75M |
| Total equity | $9.25M | $19M | $26.1M | $44M | $63.2M |
| Cash and short-term investments | $26.7M | $41.7M | $56.6M | $73.8M | $65.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $60K | $60K | $0.00 | $0.00 |
| Gross profit | $0.00 | -$-60K | -$-60K | $0.00 | $0.00 |
| Research and development expenses | $19M | $22.6M | $27.8M | $29.4M | $11.3M |
| Selling, general and administrative expenses | $12.5M | $13.7M | $15.3M | $12.2M | $10.2M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $31.5M | $36.3M | $43.1M | $41.7M | $21.4M |
| Cost and expenses | $31.5M | $36.3M | $43.1M | $41.7M | $21.4M |
| Interest income | $1.22M | $2.52M | $2.9M | $940K | $0.00 |
| Interest expense | $5.34M | $4.67M | $4.21M | $1.32M | $0.00 |
| Depreciation and amortization | $20K | $60K | $60K | $0.00 | $10K |
| Ebitda | -$-30.3M | -$-33.75M | -$-40.09M | -$-40.74M | -$-21.43M |
| Operating income | -$-31.54M | -$-36.32M | -$-43.05M | -$-41.67M | -$-21.44M |
| Total other income/expenses, net | -$-4.12M | -$-2.16M | -$-1.3M | -$-380K | $0.00 |
| Income before tax | -$-35.67M | -$-38.48M | -$-44.35M | -$-42.05M | -$-21.43M |
| Income tax expense | -$-1.17M | -$-870K | -$-1.41M | -$-1.2M | -$-4.52M |
| Net income | -$-34.5M | -$-37.61M | -$-42.94M | -$-40.85M | -$-16.92M |
| Weighted average shares outstanding | $46.4M | $36.5M | $31M | $28.6M | $25.6M |
| Weighted average diluted shares outstanding | $46.4M | $36.5M | $31M | $28.6M | $25.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $26.7M | $41.7M | $56.6M | $73.8M | $65.2M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $28.3M | $45.1M | $59.1M | $76.5M | $66.8M |
| Property, plant and equipment, net | $240K | $300K | $340K | $530K | $360K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $2.24M | $300K | $340K | $530K | $360K |
| Total assets | $30.5M | $45.4M | $59.4M | $77M | $67.2M |
| Accounts payable | $3.57M | $1.68M | $6.98M | $1.22M | $1.31M |
| Short-term debt | $5.17M | $12.6M | $4.22M | $290K | $260K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $9.48M | $17.1M | $13.6M | $9.82M | $3.76M |
| Long-term debt | $11.8M | $9.27M | $19.6M | $23.2M | $230K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $11.8M | $9.27M | $19.6M | $23.2M | $230K |
| Capital lease obligations | $60K | $120K | $180K | $450K | $490K |
| Total liabilities | $21.2M | $26.4M | $33.3M | $33M | $3.99M |
| Common stock | $20K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-216.61M | -$-182.11M | -$-144.5M | -$-101.56M | -$-60.7M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $9.25M | $19M | $26.1M | $44M | $63.2M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $16.9M | $21.8M | $23.9M | $23.5M | $490K |
| Net debt | -$-9.79M | -$-19.86M | -$-32.71M | -$-50.35M | -$-64.75M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-34.5B | -$-37.61M | -$-42.94M | -$-40.85M | -$-16.92M |
| Depreciation and amortization | $1.55B | $20K | $20K | $0.00 | $10K |
| Stock-based compensation | $4.11B | $6.85M | $7.61M | $5.2M | $4.11M |
| Change in working capital | -$-380K | -$-5.75M | -$-200K | $4.47M | $80K |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $1.89M | -$-5.3M | $5.76M | -$-90K | -$-110K |
| Net cash provided by operating activities | -$-27.75B | -$-35.03M | -$-33.64M | -$-25.71M | -$-12.49M |
| Investments in property, plant and equipment | $0.00 | -$-30K | $0.00 | $0.00 | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $0.00 | -$-30K | $0.00 | $0.00 | $0.00 |
| Common stock issued | $20.3M | $22.6M | $16.1M | $9.86M | $48.5M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $12.8B | $20.2M | $16.4M | $34.3M | $48.9M |
| Net change in cash | -$-14.98B | -$-14.87M | -$-17.26M | $8.58M | $36.4M |
| Cash at end of period | $26.7B | $41.7M | $56.6M | $73.8M | $65.2M |
| Operating cash flow | -$-27.75B | -$-35.03M | -$-33.64M | -$-25.71M | -$-12.49M |
| Capital expenditure | $0.00 | -$-30K | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$-27.75B | -$-35.06M | -$-33.64M | -$-25.71M | -$-12.49M |
Line items
Line items
Line items
About PDS Biotechnology Corporation
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
- CEO
- Frank K. Bedu-Addo
- Employees
- 21
- Beta
- 1.58
Explore
Frequently asked questions
What is the intrinsic value of PDS Biotechnology Corporation (PDSB)?
InvestorsCraft does not currently publish an intrinsic value for PDSB. How the IC value is calculated.
Is PDSB undervalued?
InvestorsCraft does not publish an undervaluation signal for PDSB at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.